Multicenter, Phase III, Open-Label, Uncontrolled Study to Assess the Safety and Efficacy of a Single Oral Dose of Palonosetron 0.75 mg in the Prevention of Chemotherapy Induced Nausea and Vomiting in Cancer Patients Undergoing Repeated Cycles of Moderately Emetogenic Chemotherapy

Trial Profile

Multicenter, Phase III, Open-Label, Uncontrolled Study to Assess the Safety and Efficacy of a Single Oral Dose of Palonosetron 0.75 mg in the Prevention of Chemotherapy Induced Nausea and Vomiting in Cancer Patients Undergoing Repeated Cycles of Moderately Emetogenic Chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2012

At a glance

  • Drugs Palonosetron (Primary) ; Dexamethasone
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Oct 2012 Trial information available on the European Clinical Trials Database.
    • 04 Oct 2012 New trial record
    • 01 Oct 2012 Results were presented at the Annual Congress of the European Society for Medical Oncology (ESMO) in October 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top